Hormone Replacement Therapy, Family History, and Breast Cancer Risk Among Postmenopausal Women

Epidemiology

Volumn 20, Issue 5, 2009, Pages 752-756

  Gramling, Robert ^a   Eaton, Charles B ^a   Rothman, Kenneth J ^b   Cabral, Howard ^b   Silliman, Rebecca A ^b   Lash, Timothy L ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b Departments of Family Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE;

AGED; ARTICLE; BREAST TUMOR; ESTROGEN THERAPY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SWEDEN;

AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SWEDEN;

EID: 73349109168     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181a71279     Document Type: Article

References (26)

1. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73:643-651.
2. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
3. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800-809.
4. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
5. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998;90:814-823.
6. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
7. Dinger JC, Heinemann LA, Mohner S, Thai do M, Assmann A. Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Womens Health. 2006;6:13.
8. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981;67:815-820.
9. Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol. 1991;134:1375-1385.
10. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142:788-795.
11. Nomura AM, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer. 1986;37:49-53.
12. Olsson H, Bladstrom A, Ingvar C, Moller TR. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer. 2001;85:674-677.
13. Bain C, Speizer FE, Rosner B, Belanger C, Hennekens CH. Family history of breast cancer as a risk indicator for the disease. Am J Epidemiol. 1980;111:301-308.
14. Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology. 1991;2:276-284.
15. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol. 2005;20:699-711.
16. Magnusson C, Colditz G, Rosner B, Bergstrom R, Persson I. Association of family history and other risk factors with breast cancer risk (Sweden). Cancer Causes Control. 1998;9:259-267.
17. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 2002;20:699-706.
18. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127:973-980.
19. McNagny SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med. 1997;127:1093-1096.
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
21. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
22. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses’ Health Study. JAMA. 1993;270:338-343.
23. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippinott-Raven Publishers; 1998.
24. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
25. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992;79:286-294.
26. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987;257:209-215.